With a survival rate of only five years, the most common and aggressive form of primary brain tumor, glioblastoma multiforme, is notoriously hard to treat using current regimens that rely on surgery, radiation, chemotherapy ...
Feb 23, 2021
0
59
Glioblastoma is among the most aggressive and devastating of cancers. While rare compared with other cancers, it's the most common type of brain cancer. Even with intensive therapy, relatively few patients survive longer ...
Feb 11, 2021
0
89
In far too many cases over the years, scientists have discovered promising new cancer treatments, only to report later that the tumor cells found ways to become resistant. These disappointing results have made overcoming ...
Feb 10, 2021
0
64
In a study of mice, researchers at the UCLA Jonsson Comprehensive Cancer Center have identified a new approach that combines an anti-psychotic drug, a statin used to lower high cholesterol levels, and radiation to improve ...
Feb 9, 2021
0
79
Glioblastoma brain tumors are especially perplexing. Inevitably lethal, the tumors occasionally respond to new immunotherapies after they've grown back, enabling up to 20% of patients to live well beyond predicted survival ...
Jan 13, 2021
0
50
The healing process that follows a brain injury could spur tumor growth when new cells generated to replace those lost to the injury are derailed by mutations, Toronto scientists have found. A brain injury can be anything ...
Jan 4, 2021
0
173
Glioblastoma is the most common malignant brain tumor in adults. Roughly five in every 100,000 people develop this type of cancer each year. The diagnosis amounts to a death sentence: Even after surgical resection followed ...
Dec 23, 2020
0
47
White blood cells are part of many immune system responses in the human body. New research shows that a specific type of those cells may cause brain cancer tissues to die—but that's not good news, according to researchers ...
Dec 7, 2020
0
37
A laboratory test developed by a research team led by Johns Hopkins University bioengineers can accurately pinpoint, capture and analyze the deadliest cells in the most common and aggressive brain cancer in adults.
Oct 15, 2020
0
69
A team of researchers from University Hospital Zurich and the University of Zurich, the Swiss Federal Institute of Technology and biotechnology company Philochem, has found fusing cytokines with antibodies to be an effective ...
